3/26
07:14 am
iron
Auregen Biotherapeutics Announces Appointment of Scott Lauder, Ph.D., as Chief Technology Officer [Yahoo! Finance]
Low
Report
Auregen Biotherapeutics Announces Appointment of Scott Lauder, Ph.D., as Chief Technology Officer [Yahoo! Finance]
3/18
09:19 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Cantor Fitzgerald from $99.00 to $132.00. They now have an "overweight" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Cantor Fitzgerald from $99.00 to $132.00. They now have an "overweight" rating on the stock.
3/7
12:26 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $85.00 price target on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $85.00 price target on the stock.
3/3
10:06 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Scotiabank from $73.00 to $75.00. They now have a "sector outperform" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Scotiabank from $73.00 to $75.00. They now have a "sector outperform" rating on the stock.
2/27
08:00 am
iron
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Low
Report
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2/27
07:32 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
2/26
08:00 am
iron
Disc Medicine to Participate in Upcoming Investor Conferences
Low
Report
Disc Medicine to Participate in Upcoming Investor Conferences
1/24
10:59 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Stifel Nicolaus from $90.00 to $94.00. They now have a "buy" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Stifel Nicolaus from $90.00 to $94.00. They now have a "buy" rating on the stock.
1/23
02:13 am
iron
Disc Medicine announces pricing of $225.5M upsized public offering [Seeking Alpha]
Low
Report
Disc Medicine announces pricing of $225.5M upsized public offering [Seeking Alpha]
1/22
09:35 pm
iron
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
1/22
09:11 am
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Scotiabank from $70.00 to $73.00. They now have a "sector outperform" rating on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Scotiabank from $70.00 to $73.00. They now have a "sector outperform" rating on the stock.
1/21
04:01 pm
iron
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
1/21
01:17 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $118.00 price target on the stock.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $118.00 price target on the stock.
1/21
12:15 pm
iron
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $90.00 price target on the stock, up previously from $83.00.
Low
Report
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $90.00 price target on the stock, up previously from $83.00.
1/21
07:45 am
iron
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission
Medium
Report
Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission
1/20
07:00 pm
iron
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
Medium
Report
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
1/17
05:46 pm
iron
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) [Yahoo! Finance]
Medium
Report
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4) [Yahoo! Finance]
1/17
04:00 pm
iron
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)
Medium
Report
Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)